Home Newsletters Cell Therapy News Neoadjuvant Immune Checkpoint Inhibitors in High-Risk Stage III Melanoma

Neoadjuvant Immune Checkpoint Inhibitors in High-Risk Stage III Melanoma

0
Scientists review and discuss the available published and ongoing clinical trials to explore the scientific background behind immunotherapy in the neoadjuvant context.
[Human Vaccines & Immunotherapeutics]

Sorry, but the selected Zotpress account can't be found.

Abstract
Exit mobile version